echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Gastric Cancer: The true clinical efficacy of nivolumab in advanced gastric cancer

    Gastric Cancer: The true clinical efficacy of nivolumab in advanced gastric cancer

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Nivolumab, a fully human antibody drug that can recognize programmed cell death receptor-1 (PD-1), has been approved for the treatment of non-small cell lung cancer ( NSCLC ), malignant melanoma, renal cell carcinoma, Classic Hodgkin’s lymphoma , head and neck cancer, malignant mesothelioma, esophageal cancer, colorectal cancer with highly unstable microsatellites andGastric cancer (GC)
    .

    NSCLC lymphoma colorectal cancerStomach cancer

    However, there is no large amount of real data on the effectiveness and safety of immunotherapy in gastric cancer
    .


    Although some tumors can grow rapidly after immunotherapy, the specific patient ratio and survival prognosis are still unclear


    immunity

    This study is a multi-center, prospective observational study designed to evaluate the clinical prognosis of patients with gastric cancer treated with nivolumab, including survival time, safety and tumor behavior
    .


    The primary endpoint is overall survival (OS), and secondary endpoints include response rate (RR), disease control rate (DCR), progression-free survival (PFS) and tumor growth rate (TGR) at the first assessment, as well as safety


    Multivariate analysis of PFS and OS

    Multivariate analysis of PFS and OS

    A total of 501 patients were recruited, of which 487 were evaluable (median age 70 years old, 71% male, 42%/44%/14% and 21% of patients with a performance status of 0/1/2) HER2-pos, 42% have ascites)
    .


    The median OS was 5.


    The median OS was 5.


    Median overall survival of HPD and non-HPD patients

    Median overall survival of HPD and non-HPD patients

    Among 282 patients with detectable lesions, the disease control rate was 39.
    4%, and the remission rate was 14.
    2% (95% CI 10.
    3-18.
    8)
    .


    Among 219 patients who can be assessed for tumor growth rate, 20.


    Among 282 patients with detectable lesions, the disease control rate was 39.


    Original source:

    Original source:

    Takahashi, Y.


    Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08) in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.